BridgeBio Oncology Therapeutics (NASDAQ:BBOT) Sets New 52-Week Low – Here’s Why

BridgeBio Oncology Therapeutics, Inc (NASDAQ:BBOT) hit a new 52-week low during mid-day trading on Wednesday . The stock traded as low as $7.60 and last traded at $7.74, with a volume of 48091 shares traded. The stock had previously closed at $8.13.

Analysts Set New Price Targets

Several brokerages have commented on BBOT. Canaccord Genuity Group began coverage on BridgeBio Oncology Therapeutics in a research report on Monday. They issued a “buy” rating and a $23.00 price objective on the stock. HC Wainwright upped their price objective on BridgeBio Oncology Therapeutics from $27.00 to $29.00 and gave the company a “buy” rating in a research report on Friday, March 6th. Stifel Nicolaus began coverage on BridgeBio Oncology Therapeutics in a research report on Tuesday, February 10th. They issued a “buy” rating and a $23.00 price objective on the stock. Finally, Weiss Ratings began coverage on BridgeBio Oncology Therapeutics in a research report on Wednesday, January 14th. They issued a “sell (d+)” rating on the stock. Four investment analysts have rated the stock with a Buy rating and one has issued a Sell rating to the company’s stock. According to data from MarketBeat, the company has an average rating of “Moderate Buy” and a consensus target price of $25.00.

BridgeBio Oncology Therapeutics Stock Down 1.0%

The stock’s 50-day simple moving average is $9.01. The stock has a market capitalization of $644.48 million, a price-to-earnings ratio of -5.27 and a beta of 0.22.

BridgeBio Oncology Therapeutics (NASDAQ:BBOT) last issued its earnings results on Tuesday, May 12th. The company reported ($526.11) earnings per share for the quarter. Equities research analysts predict that BridgeBio Oncology Therapeutics, Inc will post -2.19 earnings per share for the current fiscal year.

Institutional Inflows and Outflows

A number of institutional investors have recently added to or reduced their stakes in the business. Paradigm Biocapital Advisors LP increased its position in BridgeBio Oncology Therapeutics by 21.2% during the 4th quarter. Paradigm Biocapital Advisors LP now owns 2,261,749 shares of the company’s stock valued at $28,317,000 after purchasing an additional 395,608 shares during the period. Laurion Capital Management LP increased its position in BridgeBio Oncology Therapeutics by 40.1% during the 4th quarter. Laurion Capital Management LP now owns 1,464,938 shares of the company’s stock valued at $18,341,000 after purchasing an additional 419,138 shares during the period. Armistice Capital LLC increased its position in BridgeBio Oncology Therapeutics by 142.7% during the 4th quarter. Armistice Capital LLC now owns 1,000,000 shares of the company’s stock valued at $12,520,000 after purchasing an additional 588,000 shares during the period. Geode Capital Management LLC boosted its position in BridgeBio Oncology Therapeutics by 3.8% during the 4th quarter. Geode Capital Management LLC now owns 561,987 shares of the company’s stock valued at $7,039,000 after acquiring an additional 20,385 shares in the last quarter. Finally, Catalio Capital Management LP bought a new stake in BridgeBio Oncology Therapeutics during the 4th quarter valued at $5,142,000. Hedge funds and other institutional investors own 54.89% of the company’s stock.

BridgeBio Oncology Therapeutics Company Profile

BridgeBio Oncology Therapeutics (NASDAQ:BBOT) is a publicly traded biotechnology company focused on discovering and developing therapies for cancer. The company concentrates on translating scientific insights into clinical-stage programs aimed at addressing oncology indications with unmet medical need.

BridgeBio Oncology’s activities center on research and development of investigational therapeutics, advancing drug candidates through preclinical studies and clinical trials. Its work typically involves in-house discovery efforts and collaborations with academic and industry partners to identify targets, optimize compounds, and generate the clinical data needed to support regulatory development.

Public information about BridgeBio Oncology Therapeutics’ specific programs, geographic operations and leadership is limited in the sources available here.